comunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7013
comunitat-uji-handle3:10234/8638
comunitat-uji-handle4:
INVESTIGACION
Resumen
In the current COVID‑19 pandemic, the next generation of innovative materials with enhanced anti‑
SARS‑CoV‑2 activity is urgently needed to prevent the spread of this virus within the community.
Herein, we report ... [+]
In the current COVID‑19 pandemic, the next generation of innovative materials with enhanced anti‑
SARS‑CoV‑2 activity is urgently needed to prevent the spread of this virus within the community.
Herein, we report the synthesis of chitosan/α‑Ag 2WO4 composites synthetized by femtosecond laser
irradiation. The antimicrobial activity against Escherichia coli, Methicilin‑susceptible Staphylococcus
aureus (MSSA), and Candida albicans was determined by estimating the minimum inhibitory
concentration (MIC) and minimal bactericidal/fungicidal concentration (MBC/MFC). To assess the
biocompatibility of chitosan/α‑Ag 2WO4 composites in a range involving MIC and MBC/MFC on
keratinocytes cells (NOK‑si), an alamarBlue™ assay and an MTT assay were carried out. The SARS‑
CoV‑2 virucidal effects was analyzed in Vero E6 cells through viral titer quantified in cell culture
supernatant by PFU/mL assay. Our results showed a very similar antimicrobial activity of chitosan/α‑
Ag 2WO4 3.3 and 6.6, with the last one demonstrating a slightly better action against MSSA. The
chitosan/α‑Ag 2WO4 9.9 showed a wide range of antimicrobial activity (0.49–31.25 μg/mL). The
cytotoxicity outcomes by alamarBlue™ revealed that the concentrations of interest (MIC and MBC/
MFC) were considered non‑cytotoxic to all composites after 72 h of exposure. The Chitosan/α‑Ag 2WO4
(CS6.6/α‑Ag 2WO4 ) composite reduced the SARS‑CoV‑2 viral titer quantification up to 80% of the
controls. Then, our results suggest that these composites are highly efficient materials to kill bacteria
(Escherichia coli, Methicillin-susceptible Staphylococcus aureus, and the yeast strain Candida albicans),
in addition to inactivating SARS‑CoV‑2 by contact, through ROS production. [-]
Entidad financiadora
Serveis Centrals d’Instrumentación Científica | Ministerio de Ciencia, Innovación y Universidades | Fundação de Amparo à Pesquisa do Estado de São Paulo | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | Generalitat Valenciana | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro | Universitat Jaume I | Ministerio de Ciencia e Innovación
Código del proyecto o subvención
PGC2018094417-B-I00 | 2013/07296-2 | 2014/14171-4 | 2017/13008-0 | 2018/01677-8 | 2018/16578-5 | 2019/03722-3 | 2019/25944-8 | AICO2020 | UJI-B2019-30 | PID2019-110927RB-I00 | PROMETEO/2020/029 | UJI-B2019-37
Derechos de acceso
info:eu-repo/semantics/openAccess